[2'-5' oligoadenylate synthetase activity in patients with acute viral hepatitis and chronic type B hepatitis, and its clinical significance].
The levels of 2'-5' oligoadenylate synthetase activity (2-5AS) were measured in the lymphocytes and sera of 32 patients with acute viral hepatitis and 20 patients with HBeAg positive chronic type B hepatitis, and the relationship between the effectiveness of interferon (IFN) therapy and 2-5AS reactivity was then studied. The lymphocyte 2-5AS (L.2-5AS) and the serum 2-5AS (S.2-5AS) levels in patients with any type of acute viral hepatitis at the acute stage were significantly higher than in the healthy subjects. The 2-5AS level in cases of acute type A viral hepatitis was significantly higher than in type B and type non A non B hepatitis. However, no significant difference in the 2-5AS levels between type B hepatitis and type non A non B hepatitis was observed. After recovery, the L.2-5AS and S.2-5AS levels decreased in patients with any type of acute viral hepatitis. No significant difference between the L.2-5AS level in healthy subjects and patients with chronic type B hepatitis was observed. The S.2-5AS level was significantly higher in patients with chronic type B hepatitis than in healthy subjects. During IFN administration, the L.2-5AS and S.2-5AS levels increased, with the maximum level and maximum rate of increase obtained on the 3rd day with respect to the L.2-5AS, and after one week with respect to the S.2-5AS. Of the 20 patients with chronic type B hepatitis with positive HBe antigen, 11 showed normalization of DNA-P, 4 disappearance of HBe antigen and 2 seroconversion of HBe antigen. In cases with a higher maximum rate of increase of the L.2-5AS, the effect of IFN therapy was observed to be greater.
Komiyama
T
T
First Department of Internal Medicine, Nippon Medical School, Japan.
Akaike
M
M
Satomura
K
K
Okumura
H
H
D015088:2',5'-Oligoadenylate Synthetase / Q000378:metabolism*; D000208:Acute Disease; D000328:Adult; D002908:Chronic Disease; D005260:Female; D006509:Hepatitis B / Q000201:enzymology* / Q000628:therapy; D006513:Hepatitis B e Antigens / Q000276:immunology; D006525:Hepatitis, Viral, Human / Q000201:enzymology* / Q000628:therapy; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008214:Lymphocytes / Q000201:enzymology; D008297:Male
D006513:Hepatitis B e Antigens; D007372:Interferons; D015088:2',5'-Oligoadenylate Synthetase